Drug-induced Negative Myoclonus: A Case Report
Objective: To report on a case of drug-induced negative myoclonus in a patient with a complex oral therapy. Background: Myoclonus is a shock-like jerk due…Quercetin administration abrogates the Parkinson’s disease (PD)-like motor and non-motor symptoms and attenuates the behavioral, neurochemical and biochemical deficits induced by rotenone toxicity in rats
Objective: The present study was carried out to investigate the preventive and therapeutic effects of quercetin (a flavonol) against rotenone-induced neurotoxicity. Background: Rotenone (pesticide) induced…Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…Steroid-responsive myoclonus in the context of pembrolizumab treatment: a novel neurological phenotype.
Objective: To outline a novel immunologically-mediated neurological adverse event associated with the use of a medication class which has an expanding range of applications [1].…Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease
Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease. Background: Parkinson’s disease (PD),…Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
Objective: To report a case of clonazepam induced withdrawal emergent dyskinesia. Background: Withdrawal emergent syndrome was first described in 1973 when it was noticed that…Drug-Induced Parkinsonism May Persist Beyond Two Years After Discontinuation of Dopamine Transmission Blocking Agents
Objective: To demonstrate that patients with drug-induced parkinsonism (DIP) can remain symptomatic beyond 6 months, what majority of literature suggests, after withdrawal of causative agents.…Moving ear syndrome secondary to bromopride and response to botulinum toxin
Objective: Report a case of a rare drug-induced movement disorder, the moving ear syndrome, describe its phenomenology and its treatment with botulinum toxin Background: Since…An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases
Objective: To describe unusual cause of rhabdomyolysis in the two patients with Parkinson’s disease (PD). Background: Levodopa-induced dyskinesia (LID) is usually seen in advanced stage…Neurological complications secondary to metronidazole: Case Report
Objective: Present and discuss a case report showing neurotoxicity peripheral and central nervous system–associated with metronidazole use. Background: Due to the extensive clinical use of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.